Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer’s Disease

Turriziani, Patrizia; Smirni, Daniela; Mangano, Giuseppa Renata; Zappalà, Giuseppe; Giustiniani, Andreina; Cipolotti, Lisa; Oliveri, Massimiliano

doi:10.3233/jad-190888

Cited by 37 publications

(44 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although rTMS has been used to treat AD in clinic, specific treatment schemes are not unified, and the mechanism is unclear. Thus, the research on rTMS to treat AD needs further investigation (Alcalá‐Lozano et al., 2018; Sabbagh et al., 2019; Turriziani et al., 2019). Recent studies have focused on the cognitive impairment of rTMS in AD model mice or patients, and there are few reports on the characteristic pathological changes and the mechanism of AD lesions (Huang et al., 2017; Ma et al., 2017).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High‐frequency transcranial magnetic stimulation protects APP/PS1 mice against Alzheimer’s disease progress by reducing APOE and enhancing autophagy

2020

View full text Add to dashboard Cite

Introduction The repetitive transcranial magnetic stimulation (rTMS) has clinically wide application prospect of psychiatry and neuroscience, for its painless, noninvasive, and high efficiency. So far, rTMS has been used in the treatment of Alzheimer's disease (AD) but the underlying mechanism is not clear. Methods and Results The APP/PS1 mice at 3‐month‐old were treated by 5 Hz high‐frequency (HF) rTMS for two weeks. After rTMS treatment, the AD‐like cognitive impairments of APP/PS1 mice were investigated subsequently, and molecular mechanisms underlying was further explored. The study showed that the 2‐week rTMS at 5Hz frequency improved cognitive impairments and AD‐like pathology (including a decrease in p‐Tau, APP, Aβ, and PP2A expression) of APP/PS1 mice. Although BDNF‐TrkB signaling was significantly enhanced, no differences of SYN, PSD95 and p‐AKT were observed in the brain of APP/PS1 mice. On the contrary, the LC3Ⅱ/LC3Ⅰ ratio was elevated with a significant reduction of ApoE and p62 in mice. Conclusions rTMS exerts a potentially protective role in the prevention and treatment of AD by reducing ApoE expression and promoting autophagic flux, which provides a new insight into the mechanism of rTMS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

High‐frequency transcranial magnetic stimulation protects APP/PS1 mice against Alzheimer’s disease progress by reducing APOE and enhancing autophagy

2020

View full text Add to dashboard Cite

show abstract

“…Since most of the cognitive functions impaired in AD are related to memory recall, problem-solving, reasoning and emotional control, prefrontal regions are the main targets of NIBS. Turriziani et al [52] stimulated the right dorsolateral prefrontal cortex (DLPFC) with LF-rTMS for 10 min before a non-verbal recognition memory task. They observed improved memory performances following the real stimulation on the right DLPFC compared to the right-sham stimulation.…”

Section: Transcranial Magnetic Stimulation-tmsmentioning

confidence: 99%

A Scoping Review of Neuromodulation Techniques in Neurodegenerative Diseases: A Useful Tool for Clinical Practice?

2021

View full text Add to dashboard Cite

Background and Objectives: Neurodegenerative diseases that typically affect the elderly such as Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia are typically characterised by significant cognitive impairment that worsens significantly over time. To date, viable pharmacological options for the cognitive symptoms in these clinical conditions are lacking. In recent years, various studies have employed neuromodulation techniques to try and contrast patients’ decay. Materials and Methods: We conducted an in-depth literature review of the state-of-the-art of the contribution of these techniques across these neurodegenerative diseases. Results: The present review reports that neuromodulation techniques targeting cognitive impairment do not allow to draw yet any definitive conclusion about their clinical efficacy although preliminary evidence is very encouraging. Conclusions: Further and more robust studies should evaluate the potentialities and limitations of the application of these promising therapeutic tools to neurodegenerative diseases.

show abstract

“…Protocol Results [18] HF ** (20 Hz), bilaterally Improved action naming [19] HF (20 Hz), bilaterally Improved action naming in milder cognitive decline Improved general naming in moderate to severe cognitive decline [20] HF (20 Hz), left Improved auditory sentence comprehension, persisted for 2 months [21] HF (10 Hz), left Improved neuropsychological test scores and daily functioning [22] HF (20 Hz)/LF * 3 (1 Hz), bilaterally Improved cognitive function and mood in the HF group, persisted for 3 months [23] HF (20 Hz), bilaterally Improved cognitive function and behaviorImproved word-image association [24] HF (20 Hz), left Improved cognitive function and behavior [25] LF (…”

Section: Referencementioning

confidence: 99%

Repetitive Transcranial Magnetic Stimulation in the Treatment of Alzheimer’s Disease and Other Dementias

et al. 2021

View full text Add to dashboard Cite

Dementia is a debilitating impairment of cognitive functions that affects millions of people worldwide. There are several diseases belonging to the dementia spectrum, most prominently Alzheimer’s disease (AD), vascular dementia (VD), Lewy body dementia (LBD) and frontotemporal dementia (FTD). Repetitive transcranial magnetic stimulation (rTMS) is a safe, non-invasive form of brain stimulation that utilizes a magnetic coil to generate an electrical field and induce numerous changes in the brain. It is considered efficacious for the treatment of various neuropsychiatric disorders. In this paper, we review the available studies involving rTMS in the treatment of these dementia types. The majority of studies have involved AD and shown beneficial effects, either as a standalone, or as an add-on to standard-of-care pharmacological treatment and cognitive training. The dorsolateral prefrontal cortex seems to hold a central position in the applied protocols, but several parameters still need to be defined. In addition, rTMS has shown potential in mild cognitive impairment as well. Regarding the remaining dementias, research is still at preliminary phases, and large, randomized studies are currently lacking.

show abstract

Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer’s Disease

Cited by 37 publications

References 51 publications

High‐frequency transcranial magnetic stimulation protects APP/PS1 mice against Alzheimer’s disease progress by reducing APOE and enhancing autophagy

High‐frequency transcranial magnetic stimulation protects APP/PS1 mice against Alzheimer’s disease progress by reducing APOE and enhancing autophagy

A Scoping Review of Neuromodulation Techniques in Neurodegenerative Diseases: A Useful Tool for Clinical Practice?

Repetitive Transcranial Magnetic Stimulation in the Treatment of Alzheimer’s Disease and Other Dementias

Contact Info

Product

Resources

About